Aprea Therapeutics (APRE) has entered into a Material Transfer Agreement with MD Anderson Cancer Center. Under the agreement, Aprea will supply ...

The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.

Vail Resorts on Tuesday issued the following press release on next season’s Epic Pass pricing and expansion of access in ...

Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous ...